Omeros (OMER) closed at $16.92 on November 6, 2026, down 0.9% from the previous close, on volume of 955,443 shares (30-day average 1,072,299).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 6, 2026 | Call Spread | 20-Nov-2616 : 19 C | 200 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Globe Newswire (Tue, 3-Nov 5:41 PM ET)
Omeros faces EU setback as CHMP reiterates negative opinion for narsoplimab in TA-TMA
Market Chameleon (Fri, 16-Oct 3:05 AM ET)
Business Wire (Fri, 16-Oct 6:20 AM ET)
Omeros Corporation Reports Second Quarter 2026 Financial Results
Business Wire (Wed, 12-Aug 4:02 PM ET)
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
Business Wire (Mon, 10-Aug 8:00 AM ET)
Market Chameleon (Mon, 3-Aug 4:40 AM ET)
Omeros Delivers First Profitable Quarter as YARTEMLEA Launch Transforms Financial Trajectory
Market Chameleon (Thu, 14-May 6:17 AM ET)
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Omeros trades on the NASDAQ stock market under the symbol OMER.
As of November 6, 2026, OMER stock price declined to $16.92 with 955,443 million shares trading.
OMER has a beta of 2.96, meaning it tends to be more sensitive to market movements. OMER has a correlation of 0.16 to the broad based SPY ETF.
OMER has a market cap of $1.22 billion. This is considered a Small Cap stock.
Last quarter Omeros reported $29 million in Revenue and $.02 earnings per share. This beat revenue expectation by $16 million and exceeded earnings estimates by $.34.
In the last 3 years, OMER traded as high as $21.24 and as low as $1.13.
The top ETF exchange traded funds that OMER belongs to (by Net Assets): VTI, IWM, VXF, BRNY, XPH.
OMER has outperformed the market in the last year with a price return of +157.1% while the SPY ETF gained +10.8%. OMER has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +28.7% and +2.1%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
OMER support price is $16.38 and resistance is $17.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OMER shares will trade within this expected range on the day.
